CD38 inhibitor

DRUG CLASS:

CD38 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval lenalidomide + daratumumab / hyaluronidase Sensitive : A1	lenalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval lenalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab/hyaluronidase Sensitive: A1 - Approval daratumumab / hyaluronidase Sensitive : A1	daratumumab/hyaluronidase Sensitive: A1 - Approval daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval thalidomide + daratumumab / hyaluronidase Sensitive : A1	thalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval thalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + isatuximab-irfc Sensitive: A2 - Guideline carfilzomib + isatuximab-irfc Sensitive : A2	carfilzomib + isatuximab-irfc Sensitive: A2 - Guideline carfilzomib + isatuximab-irfc Sensitive : A2
CD38 expression	Multiple Myeloma	CD38 expression	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
PTPRC expression	Multiple Myeloma	PTPRC expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD200 expression	Multiple Myeloma	CD200 expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD27 expression	Multiple Myeloma	CD27 expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD38-H	Multiple Myeloma	CD38-H	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD38 expression	Waldenstrom Macroglobulinemia	CD38 expression	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD20 expression	Lymphoma	CD20 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3
CD38 expression	Lymphoma	CD38 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3

CD38 inhibitor

CD38 inhibitor

Associations(48)

Associations
(48)